Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks for your advice, good to see you bought at half the price at 4.00 well done, you are doing really well here. I bought SAAS today as broke new year high and results out next week is this a good move in your opinion?. i will await retrace as you advise was thinking of buying this today too, but will wait until next week
I dont know janet,ime more of a bargain basement,asda price,chart low kinda person.
so yeah,in at around 4p,but i keep clear of trying to predict peaks,because i never get um right.
so the decisions yours.....hopefully,we get a shake/pullback,to let you in.
IMO YES BUT MIGHT HAVE A SLIGHT PULL BACK AS TECHS VERY HIGH . if it keeps going like this 20p can be hit . its had a great run from 3.5p the other day however it was over 15p before ave ,GREAT TEAM HERE I TRUST THEM
Yes troajan are you in this share? is it worth buying now
Blimey...nearly at 10p,to buy
The following is an extract from information presented in the latest RNS:
Oxford, UK. GENinCode Plc (AIM: GENI), the polygenics company focused on the prevention of cardiovascular disease and ovarian cancer, announces today the publication by the American Journal of Preventive Cardiology of a study on ‘Polygenic Risk and Incident Heart Disease in a large multiethnic cohort’.1
The Kaiser Permanente Division of Research study investigated more than 63,000 adult individuals with no history of Coronary Heart Disease (CHD) who are part of the Kaiser Permanente Northern California Genetic Epidemiology Resource in Adult Health and Aging (GERA) multi-ethnic cohort. The GERA cohort followed the membership over an average of 14 years, using CARDIO inCode-Score® to assess the polygenic risk of CHD and future incidence of risk of CHD.
I think that it is the fact that this research was undertaken to include an extensive American based multi- ethnic cohort sample which could be the information that the FDA require as previous studies sampled cohorts of predominantly European ethnic diversity. They seem to have put the stamp of approval on CIC so lets hope we hear very soon.
Have a great weekend and see what Monday brings. GLA and DYOR Swissy.
Building very quickly now as more punters wake up to genincodes potential.
Nice one @ LifeOfPI I can see what you are thinking and I'm of similar thought. Was offered 8.055p to sell first thing so it would seem that a base is being developed and that they want your shares. Only a matter of seeing out this month with a cool head and hopefully we get our reward. Cheers Swissy.
Nice post @ConorM and I am pleased that I was on the right track with my own calculations earlier as I posted the below on the 27/03/24 and somebody at A J Bell has been reading the BB LOL! seriously though this blinkered vision is all centred on the FDA approval but we have many other ongoing and growing revenue streams so the prize just gets bigger and bigger. So we are $0.16Bn apart on our estimations but I won't argue with that.....would any of us? Bring it on!
Regards Cardioincode the American Heart Association AHA/ACC are now considering guideline changes for PRS to stratify patients at high genetic risk using polygenic assessment testing.. The addressable market for this being $10.5Bn and our serviceable market for CIC of $4.5Bn. During the ongoing consultant experience programme Geni have been seeing growth of 20-30 accounts per Quarter and see this continuing into 2024-2025. The Clinical Lab Fee Schedule for CIC Score is at $760 / test. About half of Physicians would order CIC if covered by insurance for those in the low to intermediate risk categories. Therefore if my calculations are correct this could equate to 8.8m prescriptions @ $760/test = $6.46Bn potential. DYOR Swissy
Extract from an article in today's Shares magazine by AJ Bell on the role of AI in medicine:
Cardiovascular disease causes over 18 million deaths a year across the globe. Discovering ahead of time who is more susceptible to developing the disease could save millions of lives.
Genincode’s (GENI:AIM) lead product CARDIO InCode is a genetic risk assessment cardiovascular test with US FDA (Food and drug administration) approval on the horizon.
The company’s LIPIDW InCode test measures susceptibility to high cholesterol. Both tests combine clinical algorithms and AI to provide advanced patient risk assessment to predict cardiovascular disease.
Analyst Emma Ulker at WH Ireland estimates the two tests have a total addressable market opportunity in the US of around $6.3 billion if approved.
216,309 + 119,864 for my SIPP plus I will be topping up my ISA tomorrow.
Have just had thought! I was wondering if the FDA and Geni have been waiting on the results detailed in the latest RNS as final details to questions that have been asked. If so then the submission could really be in the later stages before being signed off!
I know it is only speculation on my part but I really think that another AHN NHS region could be signed up and announced anytime now and perhaps FDA news which would potentially not only add to the balance sheet but also tickle the sp upwards before the BIG NEWS arrives! Speculation is always made easier when you have a good BOD and I personally think we have a Great BOD. I admit to being in Geni since IPO so have bought at the top and at the very bottom and my feelings towards the company, its products and its BOD are the same now as then, very impressed and I look forward to the company's future. Usual Caveats, Swissy.
"This is also consistent with the findings of another study that suggested that the predictive ability of a PRS was greater in younger individuals and optimally used to identify patients with borderline and intermediate clinical risk who should initiate statin therapy and intensify their lifestyle modification efforts "
Extract
"Importantly, all 12 SNPs are associated with CHD and are independent of classic risk factors (i.e., low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, blood pressure, smoking and diabetes mellitus), which is not the case for most of the SNPs included in genome-wide PRSs. The CARDIO inCode-Score® CHD PRS has been developed by GENinCode Plc for clinical use in a primary preventive setting and is commercially available in Europe. It has been shown to improve risk reclassification in a multi-ethnic population particularly at intermediate ASCVD risk, when including the PRS in the Framingham risk function [12,13]. In the secondary preventive setting, it has been associated with a higher risk of recurrence in patients with a first myocardial infarction [19,20]. CARDIO inCode-Score® is a ‘first in class’ PRS and has recently been granted De Novo status by the FDA and is currently progressing through to regulatory approval."
Yup
Tqhussian thats what uou posted the other day isnt it?
Maybe people think it be a little bit longer .ONE THING WE ALL KNOW ITS COMING
Lipid, ROCA and soon (fingers crossed) CIC.
The future looks bright!
Dont think the market has cottoned on to that late morning great news release as yet .Just gets more impressive.
This is all looking very positive with the research reiterating that the CIC code score really shows benefits especially in diagnosing younger people so that lifestyle / treatments can be implemented early which will save many lives going forward and must help our De Novo submission.
I was watching the Theranos story drama on iplayer the other night and it hit me that Americas appetite for diagnostic analysis with health issues is massive. I also wondered that in the longer term if like the Theranos strategy that GeninCode took an almost retail approach on an out of pocket pay as you go basis with their tests how many Americans would take it up as part of Health Status Check. The polygenic analysis results stay with you for life so the earliest diagnosis is the most beneficial. You could also see life insurance companies adopting the tests to mitigate risk exposure especially with Familial cases. Lets face it Life insurance companies over here already take all of your life style factors into consideration and also insist that you stand on scales to prove your weight declaration so as to score your risk to claim experience.
The possibilities are so numerous that we can only imagine at this stage so lets get FDA approval as soon as possible and then make plans. ThromboinCode and SUDDin Code to come out later this year let's not forget and ROCA score available now.
Wow hold onto your tickets guys and dolls as interesting is about to begin. GLA and DYOR Swissydog.
10p by friday night methinks.
And awaaaaay sellers remorse incoming ha ha!!!!
ALL HELPS
The potential market for GENI test on heart disease is simply to enormous to put a figure on.I for one have heart disease FDA approval and who knows where price will end up!
Increased my holding by 30% this morning, absolutely wasn't intending to add any more but this morning may prove a gift.